Trial
NCT04776018
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Intervention
TAK-981
Why stopped
Business Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-02